Prucalopride (Motegrity) for Chronic Idiopathic Constipation
Prucalopride (Motegrity) for Chronic Idiopathic Constipation
June 3, 2019 (Issue: 1573)
The FDA has approved the 5-HT4 receptor agonist
prucalopride (Motegrity – Shire) for treatment of chronic
idiopathic constipation (CIC) in adults. Prucalopride is
the only drug currently approved in the US for treatment
of CIC that stimulates...more
- EM Quigley and L Neshatian. Advancing treatment options for chronic idiopathic constipation. Expert Opin Pharmacother 2016; 17:501.
- AC Ford et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 2014; 109 Suppl 1:S2.
- A Wald. Constipation: advances in diagnosis and treatment. JAMA 2016; 315:185.
- Plecanatide (Trulance) for chronic idiopathic constipation. Med Lett Drugs Ther 2017; 59:66.
- In brief: tegaserod (Zelnorm) returns. Med Lett Drugs Ther 2019; 61:72.
- J Tack et al. Systematic review: cardiovascular safety profile of 5-HT4 agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 2012; 35:745.
- M Ke et al. Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study. Neurogastroenterol Motil 2012; 24:999.
- Y Yiannakou et al. A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation. Am J Gastroenterol 2015; 110:741.
- J Tack et al. Effect of prucalopride on symptoms of chronic constipation. Neurogastroenterol Motil 2014; 26:21.
- H Piessevaux et al. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of long-term treatment with prucalopride. Neurogastroenterol Motil 2015; 27:805.
- R Cinca et al. Randomised clinical trial: macrogol/PEG 3350+electrolytes versus prucalopride in the treatment of chronic constipation -- a comparison in a controlled environment. Aliment Pharmacol Ther 2013; 37:876.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Prucalopride (Motegrity) for Chronic Idiopathic Constipation
Article code: 1573c
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
